May increase plasma conc w/ strong CYP3A inhibitors, including but not limited to certain antivirals (eg, indinavir, nelfinavir, ritonavir, saquinavir), macrolide antibiotics (eg, clarithromycin, telithroycin, troleandomycin), antifungals (eg, itraconazole, ketoconazole, posaconazole, voriconazole), mibefradil, & nefazodone; grapefruit or grapefruit juice. May decrease plasma conc w/ strong CYP3A inducers, including but not limited to rifampin, carbamazepine, phenytoin, rifabutin, phenobarb & St. John's Wort; moderate CYP3A inducers, including but not limited to efavirenz, modafinil, bosentan, etravirine & nafcillin. May reduce effectiveness of CYP3A substrates w/ narrow therapeutic index (eg, alfentanil, fentanyl, quinidine, cyclosporine, sirolimus, tacrolimus). May also induce other enzymes & transporters (eg, CYP2C, P-gp) via the same mechanisms responsible for CYP3A induction (eg, pregnane X receptor activation). May increase plasma conc of P-gp substrates (eg, digoxin, dabigatran, colchicine, pravastatin), BCRP (eg, methotrexate, rosuvastatin, sulfasalazine), OCT1, MATE1, & MATE2K.